Modelling and simulation of placebo effect: application to drug development in schizophrenia

ISSN： 1567-567X

Source： Journal of Pharmacokinetics and Pharmacodynamics, Vol.40, Iss.3, 2013-06, pp. : 377-388

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of modelling and simulation in Phase I drug development

By Aarons L. Karlsson M.O. Mentre F. Rombout F. Steimer J.-L. van Peer A. invited COST B15 Experts

European Journal of Pharmaceutical Sciences, Vol. 13, Iss. 2, 2001-05 ,pp. : 115-122

Elsevier

Access to resources Recommend Favorite

Modelling and Simulation of the Positive and Negative Syndrome Scale (PANSS) Time Course and Dropout Hazard in Placebo Arms of Schizophrenia Clinical Trials

By >

Clinical Pharmacokinetics, Vol. 51, Iss. 4, 2012-04 ,pp. : 261-275

Adis International

Access to resources Recommend Favorite

Modelling during drug development

By Balant L.P. Gex-Fabry M.

European Journal of Pharmaceutics and Biopharmaceutics, Vol. 50, Iss. 1, 2000-07 ,pp. : 13-26

Elsevier

Access to resources Recommend Favorite

Application of metabonomics in drug development

By Keun Hector C Athersuch Toby J

Pharmacogenomics, Vol. 8, Iss. 7, 2007-07 ,pp. : 731-741

Future Medicine

Access to resources Recommend Favorite

The Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development

Current Pharmaceutical Biotechnology, Vol. 13, Iss. 8, 2012-06 ,pp. : 1500-1512

Bentham Science Publishers

Access to resources Recommend Favorite